Article
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrobial agents and chemotherapy - 1 Jun 2013
Abram Michael E, Hluhanich Rebecca M, Goodman Derrick D, Andreatta Kristen N, Margot Nicolas A, Ye Linda, Niedziela-Majka Anita, Barnes Tiffany L, Novikov Nikolai, Chen Xiaowu, Svarovskaia Evguenia S, McColl Damian J, White Kirsten L, Miller Michael D
Abstract excerpt
Elvitegravir (EVG) is an effective HIV-1 integrase (IN) strand transfer inhibitor (INSTI) in advanced clinical development. Primary INSTI resistance-associated mutations (RAMs) at six IN positions have been identified in HIV-1-infected patients failing EVG-containing regimens in clinical studies: T66I/A/K, E92Q/G, T97A, S147G, Q148R/H/K, and N155H. In this study, the effect of these primary IN mutations, alone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.